Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
HIGHLIGHTS • Alemtuzumab and cladribine are high-efficacy treatments for active MS • Both treatments attain similar rates of NEDA beyond 2-years • Early relapses were more common after cladribine than alemtuzumab • Adverse events were more common in alemtuzumab treated patients • More prior treatments is associated with more disease activity ABSTRACT Background : Highly active MS may warrant higher efficacy treatments for disease control.
1. Wallin, MT, Culpepper, WJ, Campbell, JD, et al. The prevalence of MS in the United States. Neurology 2019; 92: e1029–e1040. Google Scholar | Crossref | Medline 2. Giovannoni, G, Turner, B, Gnanapavan, S, et al. Is it time to target no evident disease activity (NEDA) in multiple sclerosis? Mult Scler Relat Disord 2015; 4(4): 329–333. Google Scholar | Crossref | Medline 3. Sormani, MP, Muraro, PA, Saccardi, R, et al.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
